Zymeworks Price to Sales Ratio 2016-2022 | ZYME
Historical PS ratio values for Zymeworks (ZYME) over the last 10 years. The current P/S ratio for Zymeworks as of March 30, 2023 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Zymeworks P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2023-03-30 |
8.76 |
|
15.14 |
| 2022-06-30 |
5.30 |
$0.58 |
9.16 |
| 2022-03-31 |
6.55 |
$0.53 |
12.34 |
| 2021-12-31 |
16.39 |
$0.51 |
32.00 |
| 2021-09-30 |
29.04 |
$0.44 |
65.65 |
| 2021-06-30 |
34.69 |
$0.41 |
84.59 |
| 2021-03-31 |
31.58 |
$0.62 |
51.02 |
| 2020-12-31 |
47.26 |
$0.78 |
60.88 |
| 2020-09-30 |
46.58 |
$0.51 |
90.54 |
| 2020-06-30 |
36.07 |
$0.64 |
56.06 |
| 2020-03-31 |
35.47 |
$0.64 |
55.41 |
| 2019-12-31 |
45.46 |
$0.84 |
53.94 |
| 2019-09-30 |
24.80 |
$0.86 |
28.92 |
| 2019-06-30 |
22.00 |
$1.50 |
14.71 |
| 2019-03-31 |
16.18 |
$1.26 |
12.87 |
| 2018-09-30 |
15.70 |
$3.23 |
4.86 |
| 2018-06-30 |
14.78 |
$3.17 |
4.66 |
| 2018-03-31 |
12.02 |
$2.42 |
4.97 |
| 2017-12-31 |
7.59 |
$3.41 |
2.23 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.517B |
$0.412B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
